^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    DLL3 expression

    i
    Other names: DLL3, Delta Like Canonical Notch Ligand 3, Drosophila Delta Homolog 3, Delta-Like Protein 3, Delta3, Delta (Drosophila)-Like 3, Delta-Like 3 (Drosophila), Delta-Like 3, SCDO1
    Entrez ID:
    10683
    Related biomarkers:
    Expression
    19d
    DLL3-Targeted PET/CT in Small Cell Lung Cancer (clinicaltrials.gov)
    P=N/A, N=20, Recruiting, The First Affiliated Hospital of Xiamen University
    New trial
    |
    DLL3 (Delta Like Canonical Notch Ligand 3)
    |
    DLL3 expression
    25d
    PET/CT Imaging of Small Cell Lung Cancer Using 89Zr-DFO-SC16.56 (clinicaltrials.gov)
    P1/2, N=53, Recruiting, Memorial Sloan Kettering Cancer Center | Trial completion date: Jun 2026 --> Jun 2027 | Trial primary completion date: Jun 2026 --> Jun 2027
    Trial completion date • Trial primary completion date
    |
    DLL3 (Delta Like Canonical Notch Ligand 3)
    |
    DLL3 expression
    25d
    Safety, Tolerability and Preliminary Efficacy of NEUK203-13 in Refractory Neuroendocrine Tumor Patients (clinicaltrials.gov)
    P1, N=9, Recruiting, Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Not yet recruiting --> Recruiting
    Enrollment open
    |
    DLL3 (Delta Like Canonical Notch Ligand 3)
    |
    DLL3 expression • DLL3 positive
    |
    cyclophosphamide • fludarabine IV
    1m
    68Ga-PFD3 PET Imaging for the Diagnosis and Evaluation of Small Cell Lung Cancer (clinicaltrials.gov)
    P1/2, N=30, Recruiting, Peking University First Hospital | Initiation date: Jun 2025 --> Oct 2025
    Trial initiation date
    |
    DLL3 (Delta Like Canonical Notch Ligand 3)
    |
    DLL3 expression
    1m
    DLL3 Expression in a Genotyped Cohort of Sporadic Medullary Thyroid Carcinomas. (PubMed, Am J Surg Pathol)
    Among cases with follow-up data (n=35), all 17 tumors with disease progression were DLL3 positive (13 RET-mutated tumors, 1 RAS-mutated tumor, and 3 RET/RAS wild-type tumors), including 5 with moderate expression and 12 with high expression. Most MTCs express DLL3; moreover, DLL3 expression is associated with lymph node metastases at diagnosis and disease progression, indicating that DLL3 may be an effective therapeutic target in MTC.
    Journal
    |
    RET (Ret Proto-Oncogene) • RAS (Rat Sarcoma Virus) • DLL3 (Delta Like Canonical Notch Ligand 3)
    |
    RAS mutation • RET mutation • RAS wild-type • DLL3 expression • DLL3 positive
    2ms
    A Study to Test How Well Different Doses of BI 764532 Are Tolerated by People With a Tumour in the Brain That is Positive for DLL3 (clinicaltrials.gov)
    P1, N=18, Active, not recruiting, Boehringer Ingelheim | Trial completion date: Jun 2026 --> Sep 2027 | Trial primary completion date: May 2026 --> Aug 2027
    Trial completion date • Trial primary completion date
    |
    DLL3 (Delta Like Canonical Notch Ligand 3)
    |
    DLL3 expression
    |
    obrixtamig (BI 764532)
    2ms
    Assessment of delta-like ligand 3 (DLL3) immunostaining in neuroendocrine tumors of the gynecological tract and comparing expression with other high-grade gynecological malignancies. (PubMed, Ann Diagn Pathol)
    In contrast, high-grade serous carcinomas lacked DLL3 expression. These findings demonstrate frequent DLL3 expression in gynecologic NETs and selected dedifferentiated malignancies, supporting DLL3 as a promising diagnostic marker and potential therapeutic target in gynecologic cancers.
    Journal
    |
    DLL3 (Delta Like Canonical Notch Ligand 3)
    |
    DLL3 expression
    2ms
    DAREON®-NEC-1: A Study in People With Advanced Extrapulmonary Neuroendocrine Cancer to Compare Obrixtamig Plus Carboplatin and Etoposide Treatment With Standard Chemotherapy (clinicaltrials.gov)
    P3, N=390, Not yet recruiting, Boehringer Ingelheim | Trial completion date: May 2030 --> Dec 2029
    Trial completion date
    |
    DLL3 (Delta Like Canonical Notch Ligand 3)
    |
    DLL3 expression
    |
    VENTANA DLL3 (SP347) Assay
    |
    carboplatin • etoposide IV • obrixtamig (BI 764532)
    2ms
    1438-0011: A study in people with advanced extrapulmonary neuroendocrine cancer to compare obrixtamig plus carboplatin and etoposide treatment with standard chemotherapy. (2025-523869-22-00)
    P2/3, N=74, Not yet recruiting, Boehringer Ingelheim International GmbH, Boehringer Ingelheim Espana S.A.
    New P2/3 trial
    |
    DLL3 (Delta Like Canonical Notch Ligand 3)
    |
    DLL3 expression
    |
    VENTANA DLL3 (SP347) Assay
    |
    carboplatin • etoposide IV • obrixtamig (BI 764532)
    2ms
    1438-0012: DAREON-Lung-1: A study in people with advanced small cell lung cancer to compare obrixtamig plus atezolizumab, carboplatin, and etoposide treatment with standard chemotherapy. (2025-520565-51-00)
    P2/3, N=105, Not yet recruiting, Boehringer Ingelheim International GmbH, Boehringer Ingelheim Espana S.A.
    New P2/3 trial
    |
    DLL3 (Delta Like Canonical Notch Ligand 3)
    |
    DLL3 expression
    |
    VENTANA DLL3 (SP347) Assay
    |
    Tecentriq (atezolizumab) • carboplatin • etoposide IV • obrixtamig (BI 764532) • Actemra IV (tocilizumab)
    2ms
    RAGNAR: Refractory Advanced diGestive Neuroendocrine Carcinomas Treated With tARlatamab (clinicaltrials.gov)
    P2, N=87, Recruiting, Grupo Espanol de Tumores Neuroendocrinos
    Trial initiation date
    |
    DLL3 (Delta Like Canonical Notch Ligand 3)
    |
    DLL3 expression
    |
    5-fluorouracil • irinotecan • leucovorin calcium • Imdelltra (tarlatamab-dlle)
    3ms
    This Study is an Open-lable, Early Study to Evaluate the Safety, Feasibility, Cytokinetics, and Preliminary Efficacy of GC511B in DLL3+ Relapsed/Refractory Small Cell Lung Cancer. (clinicaltrials.gov)
    P1, N=55, Recruiting, Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Not yet recruiting --> Recruiting | Initiation date: Nov 2025 --> Mar 2026
    Enrollment open • Trial initiation date • First-in-human
    |
    DLL3 (Delta Like Canonical Notch Ligand 3)
    |
    DLL3 expression